Silver Book Fact

Vaccines in development 2013

Biopharmaceutical research companies are developing 271 vaccines for infectious diseases, cancer, neurological disorders, allergies, and other diseases.

Pharmaceutical Researchers and Manufacturers of America. Medicines in Development: Vaccines–A report in the prevention and treatment of disease through vaccines. Washington, D.C.: PhRMA; 2013. http://phrma.org/medicines-in-development-for-vaccines-2013

Reference

Title
Medicines in Development: Vaccines–A report in the prevention and treatment of disease through vaccines
Publisher
PhRMA
Publication Date
2013
Authors
Pharmaceutical Researchers and Manufacturers of America
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Cost of pneumonia vaccine
    Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.  
  • Diptheria vaccine significantly reduced annual cases
    Vaccination has played a significant role in reducing diphtheria cases from 80,000 in 1975 to less than 10,000 per year.  
  • Life years saved from infectious disease eradication
    Infectious disease eradication in the U.S. led to the following annual life years saved (LYS): 5,811,852 for measles 42,702 for tetanus 212,690 for polio 1,685,740 for smallpox  
  • Use of pneumonia vaccine in children reduced rates in adults age 65+
    Within a year of introduction of PCV7 (7-valent pneumococcal conjugate vaccine) for use in the U.S. in infants, children under 2 years, and high risk children ages 2 to 4;…  
  • Cost effectiveness of MMR vaccine
    For every dollar spent on the MMR (measles, mumps, and rubella) vaccine, $21 is saved.